期刊文献+

基因工程腺病毒治疗裸鼠骨肉瘤肺转移的实验研究 被引量:5

Effect of genetically modified adenovirus H101 on nude mice model of osteosarcoma with lung metastasis
原文传递
导出
摘要 目的:研究基因工程腺病毒对骨肉瘤裸鼠模型局部原发肿瘤和远处转移灶的作用。方法:裸鼠皮下注射人骨肉瘤细胞株OS-732,建立骨肉瘤裸鼠模型,随机分为处理组(15只)和对照组(14只)。处理组以基因工程腺病毒(H101)瘤内注射,对照组以DMEM液注射。观察局部肿瘤和远处转移灶的肿瘤平均直径和质量,以及肺转移结节数和肺转移总结节数,以流式细胞仪分析处理组和对照组局部肿瘤的异倍体含量。结果:处理组和对照组局部肿瘤及远处转移灶的肿瘤平均直径、质量和异倍体含量差异无统计学意义,P>0.05。处理组和对照组的肺转移结节数分别为4.20±2.33和3.57±2.20,差异无统计学意义,t=0.745,P=0.463;两组肺转移总结节数分别为11.00±6.43和9.57±6.17,差异也无统计学意义,t=0.611,P=0.547。结论:H101不能明显抑制裸鼠骨肉瘤的局部肿瘤生长和远处转移。 OBJECTIVE:To investigate the effect of genetically modified adenovirus H101 on nude mice model of human osteosarcoma. METHODS; Incubate OS-732 cell line on 29 nude mice were divided into treatment group and control group, The genetically modi lied adenovirus H101 was injected into the primary tumor in the treatment group and DMEM was injected intratumorally in the control group. Observe the mean diameter and the wet weight of the primary tumor and the distant metastasis. Calculate the lung metastasis nodules and the total metastasis nodules. They were also analyzed by FCM. RESULTS: There were no significant differences with the mean diameter,wet weight and the aneuploid percents of the primary tumors and the distant metastasis tumors between the treatment group and the control group (P〉0. 05). The lung metastasis nodules of the treatment group and the control group were 4.20±2.33 and 3.57±2.20, respectively. There were no significant differences(t=0. 745, P=0. 463) ; The total lung metastasis nodules of the treatment group and the control group are 11.00±6.43 and 9.57±6.17, respectively. There are no significant differences (t=0. 611, P=0. 547). CONCLUSION: The genetically modified adenovirus H101 can not inhibit the growth and metastasis tendency of the osteosarcoma in this nude mice model.
出处 《中华肿瘤防治杂志》 CAS 2009年第14期1066-1068,共3页 Chinese Journal of Cancer Prevention and Treatment
关键词 骨肉瘤/病理学 基因表达 肺肿瘤/继发性 小鼠 osteosarcoma/pathology gene expression lung neoplasms/secondary mice, nude
  • 相关文献

参考文献3

二级参考文献37

  • 1夏忠军,常建华,张力,姜文奇,管忠震,刘基巍,张阳,胡晓桦,吴国华,王华庆,陈正常,陈建超,周清华,陆建伟,樊青霞,黄建瑾,郑晓.基因工程腺病毒(H101)瘤内注射联合化疗治疗头颈部及食管鳞癌的Ⅲ期临床研究[J].癌症,2004,23(12):1666-1670. 被引量:50
  • 2Chen MJ, Chung-Faye GA, Searle PF, et al. Gene therapy for colorectal cancer: Therapeutic Potential[J]. Bio Drugs, 2001, 15(6):357~367.
  • 3Kirn D, Martuza RL, Zwiebel J, et al. Replication-selective virotherapy for cancer:Biological principles, risk management and future directions[J]. Nat Med, 2001, 7(7):781~787.
  • 4BischoffJR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells [J].Science, 1996, 274(5286):373~ 376.
  • 5Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selective- replicating adenovirus in combination cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer [J]. Nat Med, 2000, 6(8):879~885.
  • 6Makower D, Rozenblit A, Kaufman H, et al. Phase Ⅱ clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepato- biliary tumors with correlative p53 studies [J]. Clin Cancer Res, 2003, 9(2):693~ 702.
  • 7Ries S, Korn WM. ONYX-015: mechanisms of action and clinical potential of a replication-selective denovirus [J]. Br J Cancer,2002, 86(1):5~11.
  • 8Nemunaitis J, Khuri F, Ganly J, et al. Phase Ⅱ trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in Patients with refractory head and neck cancer [J] . J Clin Oncol, 2001, 19(2):289~298.
  • 9叶任高.内科学 [M].第 5版. 北京:人民卫生出版社, 2002: 280-312.
  • 10Khuri FR,Nemunaitis J,Ganly I,et al. a controlled trial of intratumoral ONYX-015,a selectively-replicating adenovirus,in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer [J]. Nat Med,2000,6(8):879- 885.

共引文献54

同被引文献34

引证文献5

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部